Partly focused on delivery challenges that have limited the reach of RNA medicines, new biotech company Axelyf Inc. closed a $2.6 million seed round to support development of its AXL technology and to ...

Worrisome new signals caused the U.S. FDA – which earlier this month OK’d revised labeling for Valneva SE’s chikungunya virus ...

Individuals who develop antibodies against the GluN1 subunit of NMDA receptors can develop NMDA receptor encephalitis (NMDARE), which can lead to psychosis, cognitive deficits and movement disorders.

After making a significant strategic investment in Oxganox Ltd. earlier this year, Terumo Corp. quickly returned to buy the organ preservation company. On Aug. 25, the companies announced that Terumo ...

In another deal between the two companies that could be worth more than $1 billion, Abbvie Inc. is buying Gilgamesh Pharmaceuticals Inc.’s lead candidate bretisilocin for up to $1.2 billion, including ...

Apex Biosciences Pte Ltd. has identified phosphodiesterase PDE4B inhibitors reported to be useful for the treatment of cancer, neurological disorders, inflammatory bowel disease, skin inflammation, ...

Relay Therapeutics Inc. has disclosed compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer and PIK3CA-related overgrowth spectrum ...

Osteoarthritis arises from breakdown of cartilage covering bone joints, which leads to chronic inflammation, and current therapies provide only short-term relief with risk of side effects. In an ...

Haisco Pharmaceutical Group Co. Ltd. has synthesized soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of cardiovascular, renal and respiratory disorders.

Despite having lower smoking habits than other groups in the U.S., Black Americans are more likely to develop lung cancer, ...

The U.S. and the EU have signed off on a trade deal, which makes some important provisions for generic pharmaceuticals. However, Medtech Europe said in an Aug. 21 statement that it is concerned about ...

The U.S. FDA has approved Dawnzera (donidalorsen) from Ionis Pharmaceuticals Inc. as a prophylactic therapy for rare and genetic disease hereditary angioedema (HAE). The approval came as expected, as ...